Dinesh Chandra Doval

机构：Rajiv Gandhi Cancer Institute and Research Centre · ORCID：0000-0002-6191-563X

发表论文 139 篇 · 总被引 2744 次 · h-index 27

代表论文

• DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. (2024 · Journal of Clinical Oncology · 被引 32)
• Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India (2021 · South Asian Journal of Cancer · 被引 18)
• Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India (2021 · Asia-Pacific Journal of Clinical Oncology · 被引 9)
• Detection of human papillomavirus infection in oral cancers reported at dental facility: assessing the utility of FFPE tissues (2021 · Medical Oncology · 被引 6)
• Abstract PD18-11: Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07) (2023 · Cancer Research · 被引 5)
• Role of Circulating Tumor Cells in Determining Prognosis in Metastatic Breast Cancer (2022 · South Asian Journal of Cancer · 被引 5)